18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: Biodistribution and radiation dosimetry

Journal of Nuclear Medicine

Volumn 54, Issue 9, 2013, Pages 1551-1556

  Challapalli, Amarnath ^a   Kenny, Laura M ^a   Hallett, William A ^b   Kozlowski, Kasia ^a   Tomasi, Giampaolo ^a   Gudi, Mihir ^a   Al Nahhas, Adil ^c   Coombes, R Charles ^a   Aboagye, Eric O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Imanova Ltd   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Apoptosis; Biodistribution; Caspase 3; Dosimetry

Indexed keywords

CASPASE 3; FLUORODEOXYGLUCOSE F 18; FLUORODEOXYGLUCOSE F 18 1 [[1 (2 FLUOROETHYL) 1H [1,2,3] TRIAZOL 4 YL]METHYL] 5 [2(2,4 DIFLUOROPHENOXYMETHYL) PYRROLIDINE 1 SULFONYL]ISATIN; TRACER; UNCLASSIFIED DRUG; (18)F ICMT11; (18)F-ICMT11; AZIDE; DIAGNOSTIC AGENT; INDOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ABNORMAL BLOOD PRESSURE; ADULT; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BLADDER; BLOOD SAMPLING; BLURRED VISION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GALLBLADDER; HEADACHE; HEPATOBILIARY SYSTEM; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INTESTINE WALL; LARGE INTESTINE; LIVER; MALE; NEUTROPENIA; NON INVASIVE PROCEDURE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE DISTRIBUTION; RADIATION SAFETY; RADIOACTIVITY; SMALL INTESTINE; URINALYSIS; 18F-ICMT-11; AGED; ANTIBODY SPECIFICITY; BIODISTRIBUTION; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; RADIATION DOSE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

18F-ICMT-11; APOPTOSIS; BIODISTRIBUTION; CASPASE-3; DOSIMETRY;

AGED; APOPTOSIS; AZIDES; CASPASE 3; FEMALE; HUMANS; INDOLES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84887350708     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.118760     Document Type: Article

References (35)

1. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene. 2003;22:8543-8567.
2. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci. 1997;22:299-306.
3. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004;4:592-603.
4. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov. 2002;1:111-121.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100: 57-70.
6. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9:231-241.
7. Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6:99-104.
8. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer. 2000;89:2145-2152.
9. Dubray B, Breton C, Delic J, et al. In vitro radiation-induced apoptosis and early response to low-dose radiotherapy in non-Hodgkin's lymphomas. Radiother Oncol. 1998;46:185-191.
10. Faried A, Sohda M, Nakajima M, Miyazaki T, Kato H, Kuwano H. Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma. Eur J Cancer. 2004;40: 2804-2811.
11. Jia Y, Dong B, Tang L, et al. Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer. Tumour Biol. 2012;33:1151-1158.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
13. Nguyen QD, Challapalli A, Smith G, Fortt R, Aboagye EO. Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase- 3/7 specific radiotracer [18F]ICMT-11. Eur J Cancer. 2012;48:432-440.
14. Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase- 3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci USA. 2009;106: 16375-16380.
15. Fortt R, Smith G, Awais RO, Luthra SK, Aboagye EO. Automated GMP synthesis of [18F]ICMT-11 for in vivo imaging of caspase-3 activity. Nucl Med Biol. 2012;39:1000-1005.
16. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
17. Rhodes CG, Wollmer P, Fazio F, Jones T. Quantitative measurement of regional extravascular lung density using positron emission and transmission tomography. J Comput Assist Tomogr. 1981;5:783-791.
18. Graham MM, Peterson LM, Link JM, et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med. 1997;38:1631-1636.
19. Thomas SR, Stabin MG, Chen CT, Samaratunga RC. MIRD pamphlet no. 14 revised: a dynamic urinary bladder model for radiation dose calculations. Task Group of the MIRD Committee, Society of Nuclear Medicine. J Nucl Med. 1999;40:102S-123S.
20. The 2007 recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37:1-332.
21. 1990 recommendations of the International Commission on Radiological Protection. ICRP publication 60. Ann ICRP. 1991;21:1-201.
22. Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). ICRP publication 80. Ann ICRP. 1998;28:1-126.
23. Jones SC, Alavi A, Christman D, Montanez I, Wolf AP, Reivich M. The radiation dosimetry of 2 [F-18]fluoro-2-deoxy-D-glucose in man. J Nucl Med. 1982;23:613-617.
24. Brown WD, Oakes TR, DeJesus OT, et al. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. J Nucl Med. 1998;39:1884-1891.
25. Radioactive drugs for certain research uses. Code of Federal Regulations Title 21, Part 361.1. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch. cfm?fr5361. Accessed July 16, 2013.
26. Martincic DS, Virant Klun I, Zorn B, Vrtovec HM. Germ cell apoptosis in the human testis. Pflugers Arch. 2001;442:R159-R160.
27. Höglund J, Shirvan A, Antoni G, et al. 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med. 2011;52:720-725.
28. Kemerink GJ, Boersma HH, Thimister PW, et al. Biodistribution and dosimetry of 99mTc-BTAP-annexin-V in humans. Eur J Nucl Med. 2001;28:1373-1378.
29. Kemerink GJ, Liem IH, Hofstra L, et al. Patient dosimetry of intravenously administered 99mTc-annexin V. J Nucl Med. 2001;42:382-387.
30. Kemerink GJ, Liu X, Kieffer D, et al. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J Nucl Med. 2003;44:947-952.
31. Ng KK, Donat R, Chan L, Lalak A, Di Pierro I, Handelsman DJ. Sperm output of older men. Hum Reprod. 2004;19:1811-1815.
32. Schmelz HU, Meiswinkel J, Port M, et al. Apoptosis in non-tumorous adult human testis tissue: comparison of so-called 'normal' testis tissues. Urol Int. 2005;74:349-354.
33. Johnson L. Spermatogenesis and aging in the human. J Androl. 1986;7:331-354.
34. Ohtsuki K, Akashi K, Aoka Y, et al. Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. Eur J Nucl Med. 1999;26:1251-1258.
35. Domen J. The role of apoptosis in regulating hematopoiesis and hematopoietic stem cells. Immunol Res. 2000;22:83-94.